[English, Research]基因疗法：小RNA避开癌症

StephenW

Gene therapy: Little RNA keeps cancer away

Felix Cheung

Abstract

MicroRNA research reveals therapeutic targets for liver cancer

Original article citationJin, H. et al.                                                                                                 Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell 19, 232–243  (2011).
Introduction

Liver cancer is a leading cause of death in Asia, particularly in China. Many patients infected with hepatitis develop and die from liver cancer, but advances in technology may allow gene therapy to become a suitable method of treatment.

A team of Chinese researchers led by Xuetao Cao at Second Military Medical University in Shanghai and Tsinghua University in Beijing1 have used massively parallel signature sequencing (MPSS) to analyse the miRNomes of normal human liver, hepatitis liver and cancer liver. The miRNome is the entire set of microRNAs expressed in a tissue or cell type, and MPSS is a sequencing technique for scanning miRNomes. They identified nine microRNAs that accounted for 88.2% of the miRNome in the normal human liver, one of which was the microRNA miR-199a/b-3p.

The researchers found that the expression level of miR-199a/b-3p was much lower in cancer liver than in normal human liver. They also analysed the miRNome in patients with liver cancer and further confirmed that low miR-199a/b-3p expression level corresponds to poor survival probability.

The researchers tested the therapeutic potential of miR-199a/b-3p by injecting the microRNA into mice with liver cancer. They found that miR-199a/b-3p was capable of repressing liver cancer growth and may therefore represent an alternative treatment to current chemotherapy.

The authors of this work are from:
National Key Laboratory of Medical Immunology and Institute of Immunology, Second Military Medical University, Shanghai, China; Institute of Immunology, School of Medicine, Tsinghua University, Beijing, China; Institute of Immunology, School of Medicine, Zhejiang University, Hangzhou, China; Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Shanghai, China; Department of Organ Transplantation, Shanghai Changzheng Hospital, Shanghai, China; Liver Cancer Institute and Zhongshan Hospital, Institutes of Biomedical Science, Fudan University, Shanghai, China; National Lab of Molecular Virology and Genetic Engineering, Beijing, China; Beijing Genomics Institute, Shenzhen, China; School of Life Sciences, Sun Yat-sen University, Guangzhou, China; Affiliated Tumor Hospital, Guangxi Medical University, Nanning, China.
Reference

• Jin, H. et al.  Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell 19, 232–243  (2011). | Article | PubMed | [url=http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&action=reflink&origin=npg&version=1.0&coi=1:CAS:528C%2BC3MXhvFeksbk%3D&pissn=%7BprintIssn%7D&pyear=2011&md5=b1b1b6fb84d30ec890b9f08bf985cd4d]ChemPort[/url] |
  

(6.合.彩).足球.篮球...各类投注开户下注

第一投注.现金网:招代理年薪10万以上:6668.cc

StephenW

microRNA研究揭示肝癌的治疗靶点
原来的文章引用
金蕙，等。在人类肝和肝癌miRNomes鉴定发现为肝癌的治疗靶点miR-199a/b-3p。癌细胞19，232-243（2011年）。
简介

肝癌是亚洲领先的死亡原因，尤其是在中国。肝炎病毒感染许多患者并死于肝癌，但在技术的进步可能使基因疗法成为治疗合适的方法。

一个研究小组，由中华学涛率领的曹在上海第二军医大学和清华大学在Beijing1已经使用大规模并行签名测序（MPSS）分析人类正常肝，肝炎和癌症肝癌肝miRNomes。该miRNome是在一个组织或细胞类型表达的microRNA整个集合，MPSS是一个用来扫描miRNomes测序技术。他们发现了9种小分子RNA，为88.2％，占miRNome在正常人体肝脏，其中之一是小分子RNA miR-199a/b-3p。

研究人员发现，miR-199a/b-3p表达水平明显低于肝癌症在正常人的肝脏。他们还分析了肝癌患者miRNome进一步证实，低miR-199a/b-3p表达水平相当于穷人的生存概率。

研究人员测试注射到小鼠的microRNA与肝癌的miR-199a/b-3p的治疗潜力。他们发现，miR-199a/b-3p是抑制肝癌生长的能力，因此可能代表了目前替代治疗化疗。

这项工作的作者来自：
国家重点实验室，医学免疫学与免疫学研究所，第二军医大学，上海，中国;免疫学研究院，医学院，清华大学，北京，中国，免疫学研究院，医学院，浙江大学，杭州，中国;第三肝外科，东方肝胆外科医院，上海，中国署，器官移植，上海长征医院，上海，中国系肝癌研究所，中山医院，生物医学科学研究院，复旦大学，上海，中国;国家重点实验室分子病毒学与基因工程，北京，中国北京基因组研究所，深圳，中国，生命科学，孙中山学院，广州，中国学校;附属肿瘤医院，广西医科大学，广西南宁，中国。
参考

    金蕙，等。在人类肝和肝癌miRNomes鉴定发现为肝癌的治疗靶点miR-199a/b-3p。癌细胞19，232-243（2011年）。 |文章| PubMed的| ChemPort |

limi2011321

回复 StephenW 的帖子

基因疗法：小RNA的不断远离癌症
张国标
摘要 简介
      肝癌是亚洲领先的死亡原因，尤其是在中国。肝炎病毒感染许多患者并死于肝癌，但在技术的进步可能使基因疗法成为治疗合适的方法。
      一个研究小组，由中华学涛率领的曹在上海第二军医大学和清华大学在Beijing1已经使用大规模并行签名测序（MPSS）分析人类正常肝，肝炎和癌症肝癌肝miRNomes。该miRNome是在一个组织或细胞类型表达的microRNA整个集合，MPSS是一个用来扫描miRNomes测序技术。他们发现了9种小分子RNA，为88.2％，占miRNome在正常人体肝脏，其中之一是小分子RNA miR-199a/b-3p。  
      研究人员发现，miR-199a/b-3p表达水平明显低于肝癌症在正常人的肝脏。他们还分析了肝癌患者miRNome进一步证实，低miR-199a/b-3p表达水平相当于穷人的生存概率。
      研究人员测试注射到小鼠的microRNA与肝癌的miR-199a/b-3p的治疗潜力。他们发现，miR-199a/b-3p是抑制肝癌生长的能力，因此可能代表了目前替代治疗化疗。
这项工作的作者来自：
      国家重点实验室，医学免疫学与免疫学研究所，第二军医大学;清华大学免疫学研究院，北京免疫学研究院，浙江大学医学院;上海第三肝外科，东方肝胆外科医院，上海长征医院，上海--中国系肝癌研究所，中山医院，生物医学科学研究院，复旦大学；国家重点实验室分子病毒学与基因工程，中国北京基因组研究所，深圳生命科学；孙中山学院;广西医科大学附属肿瘤医院。


[url=http://www.google.cn/dictionary?source=translation&hl=zh-CN&q=Gene therapy: Little RNA keeps cancer away  Felix Cheung    Abstract  MicroRNA research reveals therapeutic targets for liver cancer      Original article citationJin, H. et al.                                                                                                 Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell 19, 232–243  (2011).  Introduction  Liver cancer is a leading cause of death in Asia, particularly in China. Many patients infected with hepatitis develop and die from liver cancer, but advances in technology may allow gene therapy to become a suitable method of treatment.    A team of Chinese researchers led by Xuetao Cao at Second Military Medical University in Shanghai and Tsinghua University in Beijing1 have used massively parallel signature sequencing (MPSS) to analyse the miRNomes of normal human liver, hepatitis liver and cancer liver. The miRNome is the entire set of microRNAs expressed in a tissue or cell type, and MPSS is a sequencing technique for scanning miRNomes. They identified nine microRNAs that accounted for 88.2% of the miRNome in the normal human liver, one of which was the microRNA miR-199a/b-3p.    The researchers found that the expression level of miR-199a/b-3p was much lower in cancer liver than in normal human liver. They also analysed the miRNome in patients with liver cancer and further confirmed that low miR-199a/b-3p expression level corresponds to poor survival probability.    The researchers tested the therapeutic potential of miR-199a/b-3p by injecting the microRNA into mice with liver cancer. They found that miR-199a/b-3p was capable of repressing liver cancer growth and may therefore represent an alternative treatment to current chemotherapy.    The authors of this work are from:  National Key Laboratory of Medical Immunology and Institute of Immunology, Second Military Medical University, Shanghai, China; Institute of Immunology, School of Medicine, Tsinghua University, Beijing, China; Institute of Immunology, School of Medicine, Zhejiang University, Hangzhou, China; Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Shanghai, China; Department of Organ Transplantation, Shanghai Changzheng Hospital, Shanghai, China; Liver Cancer Institute and Zhongshan Hospital, Institutes of Biomedical Science, Fudan University, Shanghai, China; National Lab of Molecular Virology and Genetic Engineering, Beijing, China; Beijing Genomics Institute, Shenzhen, China; School of Life Sciences, Sun Yat-sen University, Guangzhou, China; Affiliated Tumor Hospital, Guangxi Medical University, Nanning, China.  Reference  1.Jin, H. et al.  Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell 19, 232–243  (2011). | Article | PubMed | ChemPort |       &langpair=en|zh-CN][/url]

凉白开321